The collaboration focuses on establishing and operating pathology laboratories and facilitating the commercialization of the Company's medical devices, medical equipment, diagnostics, and healthcare portfolio across the Caribbean region. This represents the Company's proposed entry into the Caribbean healthcare market.
Key Features of the Collaboration
- Implementation through a phased expansion model, commencing with Trinidad & Tobago and progressively extending to other Caribbean markets over the next three years
- ARKALL Holdings Limited will undertake 100% of the investments required for the Caribbean expansion, including establishing and scaling pathology laboratory operations
- Lords Mark Industries Limited will provide its range of IVD products, rapid test kits, biochemistry reagents, pathology laboratory products, medical equipment, dialysis machines, and other healthcare solutions
- The Company will provide technical guidance, product knowledge, training, and operational support
- ARKALL Holdings Limited will lead commercialization and market development activities across agreed Caribbean markets
- The parties will initially undertake market assessment and business planning for Trinidad & Tobago
- The Company will provide technical and product-related documentation and support for applicable product registrations and regulatory processes
Financial Projections and Market Opportunity
Based on current internal projections and business planning assessment:
- The phased Caribbean rollout has potential to generate approximately US$100 million in export revenue between FY 2026-27 and FY 2030-31
- The indicative pathology and diagnostics opportunity across identified Caribbean markets is estimated at approximately US$1.24 billion
- The Company clarifies these are forward-looking statements and internal management assessments, with actual results subject to successful implementation, regulatory approvals, market penetration, and other commercial factors
Management Commentary
Dr. Sachidanand Upadhyay, Managing Director & CEO, stated: "Our collaboration with ARKALL Holdings Limited marks an important step in taking Lord's Mark's healthcare and MedTech capabilities to a wider international market. The Caribbean expansion will allow us to combine our medical technology, pathology and dialysis capabilities with ARKALL's regional commercial presence."
A Senior Management Representative of ARKALL Holdings Limited stated: "The Caribbean presents an important opportunity to strengthen healthcare infrastructure through greater access to quality diagnostics, medical technology and specialised healthcare solutions. Beginning with Trinidad & Tobago, our objective is to build a scalable network that can progressively serve healthcare needs across the Caribbean markets."
The Company will make further disclosures as required under SEBI (LODR) Regulations, 2015.